{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:43:50Z","timestamp":1792100630436,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.09.015","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:43:44Z","timestamp":1792097024000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine Learning Models Combining [68Ga]Ga-PSMA-11 PET Radiomics and Clinical Features to Predict Overall Survival for Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA Radioligand Therapy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0378-7824","authenticated-orcid":false,"given":"Lucas","family":"Edouard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Papillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Godbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Prega-Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Subreville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Anizan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Benziane-Ouaritini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Gallinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Cabart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Teyssonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.09.015_b0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.09.015_b0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","article-title":"Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (Vision): a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Fizazi","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.015_b0015","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.euo.2023.07.018","volume":"7","author":"Kafka","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2026.09.015_b0020","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","article-title":"Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0025","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s00259-023-06281-6","article-title":"SUVmean on baseline [18F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [177Lu]Lu-PSMA I&T","volume":"50","author":"Hartrampf","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0030","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","article-title":"177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study)","volume":"49","author":"Khreish","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00259-019-04584-1","article-title":"Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks","volume":"47","author":"Rasul","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0040","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","article-title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study","volume":"22","author":"Gafita","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.09.015_b0045","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1007\/s00259-023-06187-3","article-title":"Role of [68Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer","volume":"50","author":"Ghezzo","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0050","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1007\/s00259-024-07065-2","article-title":"PSMA PET\/CT based multimodal deep learning model for accurate prediction of pelvic lymph-node metastases in prostate cancer patients identified as candidates for extended pelvic lymph node dissection by preoperative nomograms","volume":"52","author":"Ma","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0055","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41698-024-00532-x","article-title":"UroPredict: machine learning model on real-world data for prediction of kidney cancer recurrence (UroCCR-120)","volume":"8","author":"Margue","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.euo.2026.09.015_b0060","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","article-title":"Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy","volume":"49","author":"Xue","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0065","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/diagnostics11020186","article-title":"Estimating the potential of radiomics features and radiomics signature from pretherapeutic PSMA-PET-CT scans and clinical data for prediction of overall survival when treated with 177Lu-PSMA","volume":"11","author":"Moazemi","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.euo.2026.09.015_b0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","article-title":"Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)","volume":"83","author":"Seifert","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.09.015_b0075","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1109\/TMI.2008.2012036","article-title":"A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET","volume":"28","author":"Hatt","year":"2009","journal-title":"IEEE Trans Med Imaging"},{"key":"10.1016\/j.euo.2026.09.015_b0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.euo.2026.09.015_b0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.09.015_b0090","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2023.1234853","article-title":"Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"3","author":"Gutsche","year":"2023","journal-title":"Front Nucl Med"},{"key":"10.1016\/j.euo.2026.09.015_b0095","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/jpm14111068","article-title":"Predicting response to [177Lu]Lu-PSMA therapy in mCRPC using machine learning","volume":"14","author":"Gong","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.euo.2026.09.015_b0100","first-page":"128","article-title":"Prediction of lesion-based treatment response after two cycles of Lu-177 prostate specific membrane antigen treatment in metastatic castration-resistant prostate cancer using machine learning","volume":"109","author":"B\u00fclb\u00fcl","year":"2025","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2026.09.015_b0105","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","article-title":"Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with lutetium-177-PSMA-617","volume":"57","author":"Crumbaker","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2026.09.015_b0110","article-title":"Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: a retrospective multicenter cohort study","volume":"8","author":"Raychaudhuri","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2026.09.015_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1066926","article-title":"Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA","volume":"12","author":"Assadi","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2026.09.015_b0120","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.3390\/cancers13153849","article-title":"Evaluation of 68Ga-PSMA-11 PET-MRI in patients with advanced prostate cancer receiving 177Lu-PSMA-617 therapy: a radiomics analysis","volume":"13","author":"Roll","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2026.09.015_b0125","doi-asserted-by":"crossref","first-page":"33312","DOI":"10.18632\/oncotarget.26051","article-title":"Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction","volume":"9","author":"Khurshid","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2026.09.015_b0130","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.09.015_b0135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"41","author":"Tagawa","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:43:47Z","timestamp":1792097027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"alternative-id":["S2588931126002701"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.015","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Machine Learning Models Combining [68Ga]Ga-PSMA-11 PET Radiomics and Clinical Features to Predict Overall Survival for Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA Radioligand Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}